Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2018

Open Access 16.10.2017

Cerebral venous sinus thrombosis complicated by seizures: a retrospective analysis of 69 cases

verfasst von: Du-juan Sha, Jian Qian, Shuang-shuang Gu, Lu-na Wang, Fang Wang, Yun Xu

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Cerebral venous sinus thrombosis (CVST) is a rare ischemic cerebrovascular disease. The aim of this retrospective observational study was to investigate the risk factors for complication of cerebral venous sinus thrombosis by seizures and to explore the impact of such seizures on clinical outcomes. Patients with cerebral venous sinus thrombosis with or without epileptic seizures were retrospectively analyzed and compared in terms of clinical variables, causative factors, clinical presentation, and imaging data. In all, 69 patients with cerebral venous sinus thrombosis were enrolled in this study, 32 (46.38%) of whom had experienced secondary seizures. Compared with those with no seizures, significantly more patients with secondary seizures had hemiplegia (37.50 vs. 15.63%; P = 0.020), bleeding (29.40 vs. 10.81%; P = 0.047), lesions involving the frontal (31.25 vs. 10.81%; P = 0.023) and temporal lobe (43.75 vs. 8.11%; P = 0.005), and thrombosis in the superior sagittal sinus (65.63 vs. 40.54%; P = 0.036). Multivariate logistic regression analysis showed focal neurological deficits (P = 0.004, odds ratio = 5.16, 95% CI 1.99–15.76) and thrombosis of the superior sagittal sinus (P = 0.039, odds ratio = 0.13, 95% CI 0.04–0.37) were independent risk factors for secondary seizures in patients with cerebral venous sinus thrombosis. In addition, mortality rate (9.38 vs. 5.41%; P = 0.469) and 90-day excellent prognosis rate (81.25 vs. 86.47%; P = 0.793) did not differ significantly between patients with and without epileptic seizures. The presence of focal neurological deficits and thrombosis of the superior sagittal sinus are independent risk factors for secondary seizures in patients with cerebral venous sinus thrombosis, whereas mortality and 90-day prognosis have no correlation with secondary seizures.
Literatur
1.
Zurück zum Zitat Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY, American Heart Association Stroke Council and the Council on Epidemiology and Prevention (2011) Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158–1192CrossRefPubMed Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY, American Heart Association Stroke Council and the Council on Epidemiology and Prevention (2011) Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158–1192CrossRefPubMed
2.
Zurück zum Zitat Zuurbier SM, Hiltunen S, Tatlisumak T, Peters GM, Silvis SM, Haapaniemi E, Kruyt ND, Putaala J, Coutinho JM (2016) Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke 47:390–396CrossRefPubMed Zuurbier SM, Hiltunen S, Tatlisumak T, Peters GM, Silvis SM, Haapaniemi E, Kruyt ND, Putaala J, Coutinho JM (2016) Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke 47:390–396CrossRefPubMed
3.
Zurück zum Zitat Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VC, Mridula KR, Jabeen SA, Alladi S, Meena AK, Borgohain R (2012) Risk factors, clinical profile, and longterm outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam’s Institute Venous Stroke Registry, Hyderabad (India). Neurol India 60:154–159CrossRefPubMed Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VC, Mridula KR, Jabeen SA, Alladi S, Meena AK, Borgohain R (2012) Risk factors, clinical profile, and longterm outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam’s Institute Venous Stroke Registry, Hyderabad (India). Neurol India 60:154–159CrossRefPubMed
4.
Zurück zum Zitat Coutinho JM, Gerritsma JJ, Zuurbier SM, Stam J (2014) Isolated cortical vein thrombosis: systematic review of case reports and case series. Stroke 45:1836–1838CrossRefPubMed Coutinho JM, Gerritsma JJ, Zuurbier SM, Stam J (2014) Isolated cortical vein thrombosis: systematic review of case reports and case series. Stroke 45:1836–1838CrossRefPubMed
5.
Zurück zum Zitat Ferro JM, Canhão P (2014) Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep 16:523CrossRefPubMed Ferro JM, Canhão P (2014) Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep 16:523CrossRefPubMed
6.
Zurück zum Zitat Hartel M, Kluczewska E, Gancarczyk-Urlik E, Pierzchała K, Bień K, Zastawnik A (2015) Cerebral venous sinus thrombosis. Phlebology 30:3–10CrossRefPubMed Hartel M, Kluczewska E, Gancarczyk-Urlik E, Pierzchała K, Bień K, Zastawnik A (2015) Cerebral venous sinus thrombosis. Phlebology 30:3–10CrossRefPubMed
7.
Zurück zum Zitat Ferro JM, Correia M, Rosas MJ, Pinto AN, Neves G, Cerebral Venous Thrombosis Portuguese Collaborative Study Group[Venoport] (2003) Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 15:78–83CrossRefPubMed Ferro JM, Correia M, Rosas MJ, Pinto AN, Neves G, Cerebral Venous Thrombosis Portuguese Collaborative Study Group[Venoport] (2003) Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 15:78–83CrossRefPubMed
8.
Zurück zum Zitat Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators (2008) Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 39:1152–1158CrossRefPubMed Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators (2008) Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 39:1152–1158CrossRefPubMed
9.
Zurück zum Zitat Masuhr F, Busch M, Amberger N, Ortwein H, Weih M, Neumann K, Einhäupl K, Mehraein S (2006) Risk and predictors of early epileptic seizures in acute cerebral venousand sinus thrombosis. Eur J Neurol 13:852–856CrossRefPubMed Masuhr F, Busch M, Amberger N, Ortwein H, Weih M, Neumann K, Einhäupl K, Mehraein S (2006) Risk and predictors of early epileptic seizures in acute cerebral venousand sinus thrombosis. Eur J Neurol 13:852–856CrossRefPubMed
10.
Zurück zum Zitat Sidhom Y, Mansour M, Messelmani M, Derbali H, Fekih-Mrissa N, Zaouali J, Mrissa R (2014) Cerebral venous thrombosis: clinical features, risk factors, and long-term outcome in a Tunisian cohort. J Stroke Cerebrovasc Dis 23:1291–1295CrossRefPubMed Sidhom Y, Mansour M, Messelmani M, Derbali H, Fekih-Mrissa N, Zaouali J, Mrissa R (2014) Cerebral venous thrombosis: clinical features, risk factors, and long-term outcome in a Tunisian cohort. J Stroke Cerebrovasc Dis 23:1291–1295CrossRefPubMed
11.
Zurück zum Zitat Mahale R, Mehta A, John AA, Buddaraju K, Shankar AK, Javali M, Srinivasa R (2016) Acute seizures in cerebral venous sinus thrombosis: what predicts it? Epilepsy Res 123:1–5CrossRefPubMed Mahale R, Mehta A, John AA, Buddaraju K, Shankar AK, Javali M, Srinivasa R (2016) Acute seizures in cerebral venous sinus thrombosis: what predicts it? Epilepsy Res 123:1–5CrossRefPubMed
12.
Zurück zum Zitat Kalita J, Chandra S, Misra UK (2012) Significance of seizure in cerebral venous sinus thrombosis. Seizure 21:639–642CrossRefPubMed Kalita J, Chandra S, Misra UK (2012) Significance of seizure in cerebral venous sinus thrombosis. Seizure 21:639–642CrossRefPubMed
13.
Zurück zum Zitat Davoudi V, Keyhanian K, Saadatnia M (2014) Risk factors for remote seizure development in patients with cerebral vein and dural sinus thrombosis. Seizure 23:135–139CrossRefPubMed Davoudi V, Keyhanian K, Saadatnia M (2014) Risk factors for remote seizure development in patients with cerebral vein and dural sinus thrombosis. Seizure 23:135–139CrossRefPubMed
14.
Zurück zum Zitat Commission on Epidemiology and Prognosis, International League against Epilepsy (1993) Guidelines for epidemiologic studies on epilepsy. Epilepsia 34:592–596CrossRef Commission on Epidemiology and Prognosis, International League against Epilepsy (1993) Guidelines for epidemiologic studies on epilepsy. Epilepsia 34:592–596CrossRef
15.
Zurück zum Zitat Mahoney FI, Barthel D (1965) Functional evaluation: the Barthel Index. Md State Med J 14:56–61 Mahoney FI, Barthel D (1965) Functional evaluation: the Barthel Index. Md State Med J 14:56–61
16.
17.
Zurück zum Zitat Agnelli G, Verso M (2008) Epidemiology of cerebral vein and sinus thrombosis. Front Neurol Neurosci 23:16–22PubMed Agnelli G, Verso M (2008) Epidemiology of cerebral vein and sinus thrombosis. Front Neurol Neurosci 23:16–22PubMed
18.
Zurück zum Zitat Weimar C (2014) Diagnosis and treatment of cerebral venous and sinus thrombosis. Curr Neurol Neurosci Rep 14:417CrossRefPubMed Weimar C (2014) Diagnosis and treatment of cerebral venous and sinus thrombosis. Curr Neurol Neurosci Rep 14:417CrossRefPubMed
19.
Zurück zum Zitat Ferro JM1, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators(2004) Prognosis of cerebral vein and dural sinus thrombosis. Results of International study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke 35:664–670CrossRefPubMed Ferro JM1, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators(2004) Prognosis of cerebral vein and dural sinus thrombosis. Results of International study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke 35:664–670CrossRefPubMed
20.
Zurück zum Zitat Qiu Z, Sang H, Dai Q, Xu G (2015) Endovascular treatments for cerebral venous sinus thrombosis. J Thromb Thrombolysis 40:353–362CrossRefPubMed Qiu Z, Sang H, Dai Q, Xu G (2015) Endovascular treatments for cerebral venous sinus thrombosis. J Thromb Thrombolysis 40:353–362CrossRefPubMed
21.
Zurück zum Zitat Filippidis A, Kapsalaki E, Patramani G, Fountas KN (2009) Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurg Focus 27:E3CrossRefPubMed Filippidis A, Kapsalaki E, Patramani G, Fountas KN (2009) Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurg Focus 27:E3CrossRefPubMed
22.
Zurück zum Zitat Lee DJ, Ahmadpour A, Binyamin T, Dahlin BC, Shahlaie K, Waldau B (2017) Management and outcome of spontaneous cerebral venous sinus thrombosis in a 5-year consecutive single-institution cohort. J Neurointerv Surg 9:34–38CrossRefPubMed Lee DJ, Ahmadpour A, Binyamin T, Dahlin BC, Shahlaie K, Waldau B (2017) Management and outcome of spontaneous cerebral venous sinus thrombosis in a 5-year consecutive single-institution cohort. J Neurointerv Surg 9:34–38CrossRefPubMed
23.
Zurück zum Zitat Skeik N, Stark MM, Tubman DE (2012) Complicated cerebral venous sinus thrombosis with intracranial hemorrhage and mastoiditis. Vasc Endovasc Surg 46:585–590CrossRef Skeik N, Stark MM, Tubman DE (2012) Complicated cerebral venous sinus thrombosis with intracranial hemorrhage and mastoiditis. Vasc Endovasc Surg 46:585–590CrossRef
24.
Zurück zum Zitat Tufano A, Guida A, Coppola A, Nardo A, Di Capua M, Quintavalle G, Di Minno MN, Cerbone AM, Di Minno G (2014) Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfus 12(Suppl 1):s337-342 Tufano A, Guida A, Coppola A, Nardo A, Di Capua M, Quintavalle G, Di Minno MN, Cerbone AM, Di Minno G (2014) Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfus 12(Suppl 1):s337-342
25.
Zurück zum Zitat Nasr DM, Brinjikji W, Cloft HJ, Saposnik G, Rabinstein AA (2013) Mortality in cerebral venous thrombosis: results from the national inpatient sample database. Cerebrovasc Dis 35:40–44CrossRefPubMed Nasr DM, Brinjikji W, Cloft HJ, Saposnik G, Rabinstein AA (2013) Mortality in cerebral venous thrombosis: results from the national inpatient sample database. Cerebrovasc Dis 35:40–44CrossRefPubMed
26.
Zurück zum Zitat Bharatkumar VP, Rudreshkumar KJ, Nagaraja D, Christopher R (2016) Plasma S-adenosylhomocysteine: a potential risk marker for cerebral venous thrombosis. Clin Chim Acta 458:44–48CrossRefPubMed Bharatkumar VP, Rudreshkumar KJ, Nagaraja D, Christopher R (2016) Plasma S-adenosylhomocysteine: a potential risk marker for cerebral venous thrombosis. Clin Chim Acta 458:44–48CrossRefPubMed
27.
Zurück zum Zitat Korathanakhun P, Sathirapanya P, Geater SL, Petpichetchian W (2014) Predictors of hospital outcome in patients with cerebral venous thrombosis. J Stroke Cerebrovasc Dis 23:2725–2729CrossRefPubMed Korathanakhun P, Sathirapanya P, Geater SL, Petpichetchian W (2014) Predictors of hospital outcome in patients with cerebral venous thrombosis. J Stroke Cerebrovasc Dis 23:2725–2729CrossRefPubMed
28.
Zurück zum Zitat Farzi F, Abdollahzadeh M, Faraji R, Chavoushi T (2015) Seizure in pregnancy following cerebral venous sinus thrombosis. Anesth Pain Med 22:e26866 Farzi F, Abdollahzadeh M, Faraji R, Chavoushi T (2015) Seizure in pregnancy following cerebral venous sinus thrombosis. Anesth Pain Med 22:e26866
29.
Zurück zum Zitat Gadelha T, André C, Jucá AA, Nucci M (2005) Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis 19:49–52CrossRefPubMed Gadelha T, André C, Jucá AA, Nucci M (2005) Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis 19:49–52CrossRefPubMed
30.
Zurück zum Zitat Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associsted with resistance to activated protein C. Nature 369:64–67CrossRefPubMed Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associsted with resistance to activated protein C. Nature 369:64–67CrossRefPubMed
31.
Zurück zum Zitat Beghi E, D’Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, Gandolfo C, Greco G, La Neve A, Manfredi M, Mattana F, Musolino R, Provinciali L, Santangelo M, Specchio LM, Zaccara G, Epistroke Group (2011) Incidence and predictors of acute symptomatic seizures after stroke. Neurology 77:1785–1793CrossRefPubMed Beghi E, D’Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, Gandolfo C, Greco G, La Neve A, Manfredi M, Mattana F, Musolino R, Provinciali L, Santangelo M, Specchio LM, Zaccara G, Epistroke Group (2011) Incidence and predictors of acute symptomatic seizures after stroke. Neurology 77:1785–1793CrossRefPubMed
Metadaten
Titel
Cerebral venous sinus thrombosis complicated by seizures: a retrospective analysis of 69 cases
verfasst von
Du-juan Sha
Jian Qian
Shuang-shuang Gu
Lu-na Wang
Fang Wang
Yun Xu
Publikationsdatum
16.10.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1570-5

Weitere Artikel der Ausgabe 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.